Gabapentin for behavioral dyscontrol with mental retardation.
Bozikas
V
V
Bascialla
F
F
Yulis
P
P
Savvidou
I
I
Karavatos
A
A
D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D004359:Drug Therapy, Combination; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008607:Intellectual Disability / Q000150:complications* / Q000523:psychology; D001523:Mental Disorders / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D011595:Psychomotor Agitation / Q000188:drug therapy / Q000523:psychology; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin